Log In
Print this Print this

biosimilar aflibercept (FYB203)

  Manage Alerts
Collapse Summary General Information
Company Formycon AG
DescriptionBiosimilar of aflibercept
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat ophthalmic diseases
Regulatory Designation
PartnerSanto Holding GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today